RE:STADA cannabis workgroupWell it sure is clear that when looking at the credentials of all of these players that Stada is taking a pain management angle.
Fr. Kuhr spent much of her career in that space, although I'm not sure how her experience lends itself to building out a new practice and owning large P&L.....it is a proto-typical German appointment truly.
If people think that this will not move the revenue needle in a large way for LABS, I think that's naive. It's just whether the SP will reflect it is the question. Stada isn't putting all this effort into this space for shytes and giggles....so the only thing that could derail positive impact for LABS is a quality concern or inability to maintain supply....
Thanks for sharing Lemoyne....
Lemoyne wrote: I've found 2 execs that have been hired in sept 2020:
Madlen Kuhr, head of cannabis business unit for Stadapharm and Dr. Peter Adamczy, pain doctor.
The rest of the team has been hired in jan 2021, from what I found it includes 2 other pain Drs (for south and north of germany) and about 10 sales reps.
Any other input is welcome.